Last update Feb. 5, 2022

Semaglutide

Compatible

Safe substance and/or breastfeeding is the best option.

Semaglutide is an incretin hormone analog used in the treatment of type 2 diabetes. Weekly subcutaneous administration.

At the date of the last update, there was no published data available on its excretion in human milk.

Its high molecular weight and high fixation to plasma proteins make it very unlikely to pass into mothers’ milk in a clinically significant quantity. (Serrano 2015)

In addition, due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed (practically null oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk (Serrano 2015), except in premature infants and during the immediate neonatal period, in which there may be greater intestinal permeability.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe substance and/or breastfeeding is the best option.)
  • Exenatide (Safe substance and/or breastfeeding is the best option.)
  • Glibenclamide (Safe substance and/or breastfeeding is the best option.)
  • Glipizide (Safe substance and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe substance and/or breastfeeding is the best option.)
  • Insulin (Safe substance and/or breastfeeding is the best option.)
  • Maternal Sport (Safe substance and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Miglitol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Semaglutide in other languages or writings:

Tradenames

Main tradenames from several countries containing Semaglutide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0.4 - 1 %
Molecular weight 4.114 daltons
Protein Binding 99 %
VD 0.18 l/Kg
pKa 2.74 -
Tmax 72 hours
168 hours

References

  1. FDA. Semaglutide. Drug Summary. 2020 Full text (in our servers)
  2. AEMPS. Semaglutida. Ficha técnica. 2018 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

33,286

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM